Amylyx Pharmaceuticals is voluntarily withdrawing its drug Relyvrio, used to treat amyotrophic lateral sclerosis (ALS), from the market after clinical trial results showed it was no better than a placebo. The drug received full FDA approval in 2022, but further testing showed it did not meet expectations. Amylyx plans to continue gathering data on the drug’s effects on survival for future ALS research. The company is also restructuring, cutting 70% of its workforce, with enough cash to fund research programs until 2026. They have another ALS drug candidate, AMX0114, which targets the gene associated with neurodegeneration.
Source link
Amylyx Withdraws ALS Drug From Market; Restructuring Will Slash 70% of Staff
